<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="other"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CMAJ</journal-id><journal-id journal-id-type="iso-abbrev">CMAJ</journal-id><journal-id journal-id-type="publisher-id">9711805</journal-id><journal-title-group><journal-title>CMAJ : Canadian Medical Association Journal</journal-title></journal-title-group><issn pub-type="ppub">0820-3946</issn><issn pub-type="epub">1488-2329</issn><publisher><publisher-name>CMA Impact Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9435534</article-id><article-id pub-id-type="doi">10.1503/cmaj.220629</article-id><article-id pub-id-type="publisher-id">194e1135</article-id><article-categories><subj-group subj-group-type="heading"><subject>Practice</subject><subj-group><subject>Five Things to Know about &#x02026;</subject></subj-group></subj-group></article-categories><title-group><article-title>International normalized ratio and activated partial thromboplastin time testing</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chornenki</surname><given-names>Nicholas L. J.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Fralick</surname><given-names>Michael</given-names></name><degrees>MD PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Sholzberg</surname><given-names>Michelle</given-names></name><degrees>MDCM MSc</degrees></contrib><aff id="af1-194e1135">Department of Medicine (Chornenki), Queen&#x02019;s University, Kingston, Ont.; Division of General Internal Medicine (Fralick), Sinai Health, and Departments of Medicine, and Laboratory Medicine and Pathobiology (Sholzberg), St Michael&#x02019;s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ont.</aff></contrib-group><author-notes><corresp id="c1-194e1135">Correspondence to: Nicholas Chornenki, <email>20NLJC@queensu.ca</email></corresp></author-notes><pub-date pub-type="ppub"><day>29</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>29</day><month>8</month><year>2022</year></pub-date><volume>194</volume><issue>33</issue><fpage>E1135</fpage><lpage>E1135</lpage><permissions><copyright-statement>&#x000a9; 2022 CMA Impact Inc. or its licensors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions></article-meta><notes><p>
<related-article related-article-type="companion" id="RA1" vol="194" page="E1137" ext-link-type="pmc">See related article at www.cmaj.ca/lookup/doi/10.1503/cmaj.221102</related-article>
</p></notes></front><body><sec><title>International normalized ratio (INR) and activated partial thromboplastin time (aPTT) have limited clinical utility</title><p>The INR and aPTT should be used only for specific clinical indications (see Appendix 1, available at <ext-link xlink:href="www.cmaj.ca/lookup/doi/10.1503/cmaj.220629/tab-related-content" ext-link-type="uri">www.cmaj.ca/lookup/doi/10.1503/cmaj.220629/tab-related-content</ext-link>).<xref rid="b1-194e1135" ref-type="bibr">1</xref></p></sec><sec><title>Bleeding history is the most important predictor of an inherited bleeding disorder</title><p>The INR and aPTT have poor sensitivity (1.0%&#x02013;2.1%) for bleeding disorders. <xref rid="b1-194e1135" ref-type="bibr">1</xref> Clinicians considering an inherited bleeding disorder should first use a Bleeding Assessment Tool (BAT).<xref rid="b2-194e1135" ref-type="bibr">2</xref> A negative BAT score has a sensitivity approaching 100% to rule out von Willebrand disease (the most common inherited bleeding disorder).<xref rid="b2-194e1135" ref-type="bibr">2</xref> A positive BAT score should prompt referral to a hematologist for consideration of specialized coagulation testing.<xref rid="b1-194e1135" ref-type="bibr">1</xref></p></sec><sec><title>International normalized ratio and aPTT testing are not indicated before low-risk surgery or interventional radiology</title><p>Abnormal INR or aPTT results are not associated with an increased bleeding risk in the setting of low-risk procedures.<xref rid="b3-194e1135" ref-type="bibr">3</xref>,<xref rid="b4-194e1135" ref-type="bibr">4</xref> An abnormal result with no bleeding history or anticoagulant use should be repeated to rule out artifact or sample handling error. Investigation is generally not indicated for an aPTT of less than 4 seconds above the upper limit of normal.<xref rid="b2-194e1135" ref-type="bibr">2</xref></p></sec><sec><title>An abnormal INR or aPTT in a patient who is bleeding suggests a potential medical emergency</title><p>Actionable causes of bleeding such as anticoagulant use, severe liver disease or acquired hemophilia may be indicated by the elevated INR or aPTT, respectively.<xref rid="b5-194e1135" ref-type="bibr">5</xref></p></sec><sec sec-type="subjects|results"><title>Clinical history and drug pharmacokinetics are more important than INR or aPTT results in guiding clinical decision-making in patients taking direct oral anticoagulants (DOACs)</title><p>Direct oral anticoagulants variably and inconsistently affect INR and aPTT results. If a patient is bleeding, decisions on the use of a reversing blood product or drug should be based on the last reported drug dose, renal function and pharmacokinetics. In some centres, DOAC-calibrated assays are available to evaluate the presence of clinically relevant drug activity.<xref rid="b6-194e1135" ref-type="bibr">6</xref></p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Appendix 1: Indications for basic coagulation testing.(1, 2)</title>
</caption>
<media mimetype="application"
mime-subtype="pdf"
xlink:href="220629-five-at.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn id="fn1-194e1135" fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn id="fn2-194e1135"><p>This article has been peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-194e1135"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayward</surname><given-names>CPM</given-names></name><name><surname>Moffat</surname><given-names>KA</given-names></name></person-group>. <article-title>Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests</article-title>. <source>Int J Lab Hematol</source>
<year>2013</year>;<volume>35</volume>:<fpage>322</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">23480172</pub-id></mixed-citation></ref><ref id="b2-194e1135"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbaz</surname><given-names>C</given-names></name><name><surname>Sholzberg</surname><given-names>M</given-names></name></person-group>. <article-title>An illustrated review of bleeding assessment tools and common coagulation tests</article-title>. <source>Res Pract Thromb Haemost</source>
<year>2020</year>;<volume>4</volume>:<fpage>761</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32685885</pub-id></mixed-citation></ref><ref id="b3-194e1135"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Veen</surname><given-names>JJ</given-names></name><name><surname>Spahn</surname><given-names>DR</given-names></name><name><surname>Makris</surname><given-names>M</given-names></name></person-group>. <article-title>Routine preoperative coagulation tests: An outdated practice?</article-title>
<source>Br J Anaesth</source>
<year>2011</year>;<volume>106</volume>:<fpage>1</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">21148635</pub-id></mixed-citation></ref><ref id="b4-194e1135"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>IJ</given-names></name><name><surname>Rahim</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions&#x02014;Part II: Recommendations. Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe</article-title>. <source>J Vasc Interv Radiol</source>
<year>2019</year>;<volume>30</volume>:<fpage>1168</fpage>&#x02013;<lpage>84.e1</lpage>.<pub-id pub-id-type="pmid">31229333</pub-id></mixed-citation></ref><ref id="b5-194e1135"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spahn</surname><given-names>DR</given-names></name><name><surname>Bouillon</surname><given-names>B</given-names></name><name><surname>Cerny</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition</article-title>. <source>Crit Care</source>
<year>2019</year>;<volume>23</volume>:<fpage>98</fpage>.<pub-id pub-id-type="pmid">30917843</pub-id></mixed-citation></ref><ref id="b6-194e1135"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarode</surname><given-names>R</given-names></name></person-group>. <article-title>Direct oral anticoagulant monitoring: What laboratory tests are available to guide us?</article-title>
<source>Hematology Am Soc Hematol Educ Program</source>
<year>2019</year>;<volume>2019</volume>:<fpage>194</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31808890</pub-id></mixed-citation></ref></ref-list></back></article>
